The weekly litigation news digest is live. Subscribe now
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione - EP3756650
The patent EP3756650 was granted to Amgen Europe on Aug 20, 2025. The application was originally filed on Dec 26, 2012 under application number EP20172615A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP3756650
- Application Number
- EP20172615A
- Filing Date
- Dec 26, 2012
- Status
- Granted And Under Opposition
- Jul 18, 2025
- Publication Date
- Aug 20, 2025
- External Links
- Slate, Register, Google Patents
Patent Summary
Pharmaceutical compositions comprising (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione (Compound A) for treating various diseases and disorders, including cancer, pain, inflammatory diseases, and ocular neovascular diseases. The compositions comprise Compound A in combination with fillers, disintegrants, and lubricants, and may be formulated as tablets or capsules. The compositions exhibit advantageous physical and pharmacological properties, including fast disintegration, low friability, and stability.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (36) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents